Summary • Cartesian Therapeutics (RNAC) shares rose 6.9% in pre-market trading, reaching $7.18. • Director Timothy C. Barabe purchased 30,000 shares at $6.86, indicating possible insider confidence. • ...
New funding totaling 3 million euros for cancer care in Ethiopia and research in Germany ...
Fintel reports that on November 19, 2025, HC Wainwright & Co. maintained coverage of Cartesian Therapeutics (NasdaqGM:RNAC) with a Buy recommendation. Analyst Price Forecast Suggests 391.45% Upside As ...
H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $30 from $40 and keeps a Buy rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback